$DK

Yemin Ezra Uzi sold $13.5M of DK (indirect holdings)

Yemin Ezra Uzi sold 200,000 indirectly-held shares of Delek US Holdings, Inc. (DK) at an average of $67.52 ($65.75–$68.27, $13.50M total) across 4 trades on 2026-08-13 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Yemin Ezra Uzi
Published Aug 18, 2026, 12:08 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 12:34 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$DK
Neutral
medium confidence
Mentioned
$DK
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DKNeutralLow
01

Why it matters

The newest disclosed fact is the director’s open-market sale of 200,000 shares at a weighted average price of about $67.52, totaling about $13.50M, executed Aug. 13 under a pre-arranged 10b5-1 plan.

02

Market read

Traders may briefly reassess DK sentiment due to insider selling, but the 10b5-1 structure and lack of fundamental updates limit trading impact.

03

What to watch

The filing does not disclose whether other insiders or the company itself made offsetting purchases, nor does it provide post-sale performance context.

Relevance 6/10Novelty 4/10Timing: Form 4 filed Aug. 17, covering sales executed Aug. 13.

Background

The article is an SEC Form 4 insider transaction disclosure for Delek US Holdings, Inc. (DK).

Company-level read

Ticker impact

$DKNeutralMedium confidence
Context

Delek US Holdings director Yemin Ezra Uzi sold about 200,000 shares in an open-market transaction worth about $13.5M, per Form 4 filed Aug. 17.

Expected impact

Low likelihood of a sustained price move solely from this filing; any impact would be sentiment-driven and short-lived.

Evidence & confidence

The filing is a routine Form 4 open-market sale with a pre-arranged 10b5-1 plan, and it does not include new company fundamentals, guidance, or regulatory/legal developments.

Market effects

No direct sector read-through; this is company-specific insider trading disclosure.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations, so traders may ignore it.

Key entities

  • Delek US Holdings, Inc.

    Subject of the Form 4 insider transaction disclosure (DK).

  • Yemin Ezra Uzi

    Director who sold shares via an open-market transaction under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MPCMed

BTIG warns oil refining stocks face potential correction after record gains

BTIG warns that oil refining stocks may face a correction after the S&P 500 Oil & Gas Refining and Marketing Index gained 124% year-to-date, its best performance in 30 years. The index is 122% above its 200-week moving average, with a weekly RSI of 81. Historically, similar conditions led to declines 7 out of 8 times, with a median 12-week return of -7.2%. BTIG identifies Marathon Petroleum, Valero, Phillips 66, PBF Energy, and Delek Holdings as having poor risk-reward profiles.

$DKMed

Why Delek Holdings Stock Triumphed on Tuesday

Delek US Holdings (DK) will join the S&P SmallCap 600 index on Sept. 21, replacing Brinker International. The stock rose over 5% on the news, likely due to increased visibility and potential index fund inclusion. The change does not alter the company's fundamentals.

$DKMed

Is DK a Buy Now as Cash Flow Improves Despite Refining Cycle Risks?

Delek US Holdings (DK) reported improved cash flow in Q2, with $262.9M from operations. Management expects $220M annual free-cash-flow improvement. DK trades at a forward P/E of 7.1 and P/S of 0.36. Risks include leverage, crack-spread volatility, and regulatory uncertainty. Zacks ranks DK as a Strong Buy with A-rated Value and Growth scores.

$DKMedAI 8/10

Up another 12% Friday, this AI-picked energy stock is now up +90%

Delek US Holdings (DK) surged 11.6% on Friday, reaching near a 52-week high of $71.47, extending its 90% gain since March. The energy company reported Q2 EPS of $5.48, beating estimates by 148%, with EBITDA up 279% quarter-over-quarter. InvestingPro's AI models identified Delek's potential before its rally, citing strong momentum, earnings turnaround, and cost discipline. The company's performance highlights include record refining margins and operational improvements. InvestingPro members recei